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ABSTRACT
Objectives: Rituximab (RTX) is a biological treatment
used off-label in patients with systemic lupus
erythematosus (SLE). This survey aimed to investigate
the off-label use of RTX in Europe and compare the
characteristics of patients receiving RTX with those
receiving conventional therapy.
Methods: Data on patients with SLE receiving RTX
were taken from the International Registry for Biologics
in SLE retrospective registry and complemented with
data on patients with SLE treated with conventional
therapy. For nationwide estimates of RTX use in
patients with SLE, investigators were asked to provide
data through case report forms (CRFs). Countries for
which no data were submitted through CRFs,
published literature and/or personal communication
were used, and for European countries where no data
were available, estimates were made on the
assumption of similarities with neighbouring countries.
Results: The estimated off-label use of RTX in Europe
was 0.5%–1.5% of all patients with SLE. In
comparison with patients with SLE on conventional
therapy, patients treated with RTX had longer disease
duration, higher disease activity and were more often
treated with immunosuppressives. The most frequent
organ manifestations for which either RTX or
conventional therapy was initiated were lupus nephritis
followed by musculoskeletal and haematological. The
reason for treatment was, besides disease control,
corticosteroid-sparing for patients treated with
conventional therapy.
Conclusions: RTX use for SLE in Europe is restrictive
and appears to be used as a last resort in patients for
whom other reasonable options have been exhausted.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an
inflammatory autoimmune disease with a
wide spectrum of clinical manifestations.
This diversity is a reflection of the dysregula-
tion of several components of the immune
system, resulting in B-cell hyperactivity and
production of autoantibodies.1
Most therapies for SLE are off-label. Thus,
conventional immunosuppressants (IS) such
as azathioprine, methotrexate and mycophe-
nolate mofetil are widely used, but are not
approved for this disease. Not even the ‘gold
standard’ treatment for severe lupus and
lupus nephritis (LN), cyclophosphamide
(CYX), has been approved by either the
Food and Drug Administration (FDA) or
European Medicines Agency (EMA),
although in some countries the indications
may be listed in the prescribing information.
In addition, these therapies can be associated
with severe adverse effects, and few patients
reach durable full remission.2
The development of biological therapies
has dramatically changed the treatment for
inflammatory autoimmune diseases such as
rheumatoid arthritis (RA), Crohn’s disease,
psoriasis and multiple sclerosis. Therefore,
biological therapies may offer new ways of
treating SLE. As a consequence, experimen-
tal use of biologics targeting B-cell activity
has escalated during the past decade, in par-
ticular rituximab (RTX) (MabThera, Rituxan)
and belimumab (Benlysta).
Belimumab is a B-cell directed anticytokine
agent, leading to downregulation of B-cell
activity and hence lower levels of Ig, includ-
ing autoantibodies. Positive results with beli-
mumab led to approval for treatment of SLE
by both EMA and FDA.3 4
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RTX is an antibody directed to CD20, a B-cell surface
marker, which has been shown to be effective in deplet-
ing B cells in vivo and is approved for treatment of
B-cell malignancies and for autoimmune diseases such
as RA5 and ANCA-associated vasculitis.6 7 Over the past
several years, off-label use of RTX in SLE has emerged
as one of the biological therapies used in clinically chal-
lenging cases. Two controlled trials with RTX performed
in the USA failed to meet their primary endpoints when
RTX was added to conventional therapy as compared
with the addition of placebo to the same.8 9 The patients
in the trials had active SLE but were not required to
have failed prior conventional therapy. However, in the
renal lupus trial, many exploratory endpoints at
78 weeks were met, both serological and clinical.
Multiple, mostly uncontrolled observational, studies have
suggested that RTX provides significant benefits when
given to patients with severe or refractory SLE, some-
times in conjunction with CYX.10–20 Thus, as RTX is not
approved for treatment of SLE, these reports raised the
question of how widely RTX is used in SLE and for what
specific indications.
The use of registries, where data are collected system-
atically on well-characterised patient populations treated
with specific agents, is an important source of informa-
tion about real-life efficacy and safety. The European
registries, ARTIS (Sweden),21 BSRBR (UK),22 DAN-BIO
(Denmark)23 and GRAID (Germany),24 just to name a
few, have contributed to the knowledge of both positive
and negative aspects of studied agents in the treatment
of rheumatic diseases. Therefore, we have initiated the
International Registry for Biologics In SLE (IRBIS), in
which data are collected retrospectively and prospectively
on patients with lupus treated with biologics. The IRBIS
registry was approved by the Systemic Lupus International
Collaborating Clinics (SLICC) group in 2009.
The objective of this study was to investigate the extent
of off-label use of RTX in SLE in Europe, and for what
specific indications. It is a compilation of data from the
European dataset in IRBIS, published material and data
provided by participating investigators.
METHODS
Data collection
We used data submitted by the European contributors to
the IRBIS registry on RTX-treated patients (demographic,
disease-specific and treatment). Contributors were asked
to provide additional information on the number of
patients with SLE at their centres, on patients with SLE
within their region and estimates for the whole country
in specific case report forms (CRFs). As a control, data
were also collected on patients who were started on con-
ventional IS therapy not including corticosteroids and
antimalarials. Any patient on RTX or conventional treat-
ment from 2010 to 2013 was allowed for inclusion.
Data from the CRFs were complemented with pub-
lished data and by personal communication with
participating investigators. Twenty-nine centres from 12
countries participated (table 1).
The hierarchy of data was: (1) data from the partici-
pating investigators’ registries; (2) data from CRFs; (3)
data from published studies; (4) data provided through
direct contact with participating physicians.
For countries not represented in the IRBIS collabor-
ation, and where therefore no data were available, esti-
mates were made on the assumption of similarities with
neighbouring countries.
Patients
All patients fulfilled the revised and/or updated
American College of Rheumatology (ACR) criteria.
Ethical approval for the study was obtained in countries
where this was required and all patients gave their oral
and/or written consent.
The anonymity of participating patients was main-
tained in accordance with Good Clinical Practice (GCP)
guidelines. For data collection and management pur-
poses, patients were identified by a patient number only.
Documents identifying the patient were not submitted
to the registry centre.
Statistics
For the descriptive data, means and SDs were calculated.
For comparisons between groups, unpaired t-test or
Mann-Whitney U test was used for normally distributed
and non-parametric data, respectively, using SPSS (no 21).
RESULTS
Estimates of number of patients with SLE and the use of
RTX in Europe
Contributing centres and patient referrals
We inquired which patient subsets were seen at the par-
ticipating centres and how these patients were referred
Table 1 Countries and centres that provided information
for this study
Country
Sites/
country Site/region represented
Belgium 1 Belgium
Denmark 1 Copenhagen
France 1 Paris
Germany 1 Central Germany
Greece 1 Crete
Hungary 1 Southeast Hungary
Italy 4 Tuscany (2), Veneto, Lazio
Spain 13 Bizkaia, Andalucia (2),
Madrid, Catalonia (3),
Balearic Islands, Asturias,
Jaen, Valencia, Zaragoza,
Granada
Sweden 2 Stockholm, Lund
The
Netherlands
2 Leiden, Amsterdam
Turkey 1 Istanbul
UK 1 London
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to the site. For most centres (17 out of 29), patients with
SLE were seen from a well-defined region, or from the
whole country, and referred to them by the primary
physician.
Participating investigators were asked to provide infor-
mation on the number of centres within their own
region where patients with SLE were likely to be treated
with RTX. Centres within the same region and with
similar treatment strategies ranged from 1 to 20; only five
centres responded that they were the sole centre where
patients with SLE were treated with RTX in their region.
Patients with SLE at each participating centre
Most of the rheumatology (SLE) specialty centres repre-
sented in this study had 200–300 patients with SLE, of
whom generally <5% were treated with RTX, with some
notable exceptions (table 2). It can be seen that there
was a wide range in the proportion of patients treated
with conventional therapies, and data provided from
Spain and Italy, where there are several sites, showed
clear regional variation.
Estimates of patients with SLE and RTX use in 31 European
countries
To address the prevalence of SLE and the use of RTX in
patients with SLE in Europe, participating centres were
asked to provide data about the number of patients with
SLE and the number of patients with SLE treated with
RTX in their country. These data were complemented
with the data from published medical journal articles
and publicly available healthcare sources.
The prevalence of SLE in countries with contributing
centres ranged from 1 to 13 per 10 000. For some of the
countries, the distribution of ethnical groups within the
country’s population may account for higher prevalence
in some regions, since people with Afro-Caribbean and
Asian origins have been shown to have a higher SLE
prevalence than Caucasians.25–27 Based on these data,
we calculated that 0.6%–1.6% of patients with SLE were
treated with RTX (table 3).
To get an estimate for the prevalence of SLE and RTX
use in countries under the jurisdiction of the EMA, the
remaining EU countries and the EFTA countries,
Iceland, Liechtenstein and Norway, were included. For
these countries, no data or information through per-
sonal communication are available. Instead, estimates
were made on the assumption of similarities with neigh-
bouring countries (table 3).
With a population of around 573 million, we estimated
that the incidence of patients with SLE is roughly
between 156 000 and 269 000, giving an overall preva-
lence of 4.1–7.1/10 000, subject to significant nation-
wide and regional variabilities. Out of these patients, our
analyses indicate that between 0.5% and 1.5% were
treated with RTX at the time of data collection (table 3).
Analysis of RTX-treated patients
After estimation of the prevalence of SLE and RTX use
in Europe, we wanted to investigate on what premises
RTX is prescribed.
Demographics of patients with SLE
One hundred and three RTX-treated patients and 72
conventional IS-treated patients were included in this
analysis, and their demographics are listed in table 4.
The majority (93% and 91%, respectively) was Caucasian,
and smaller proportions were Latino/South African,
Asian/Indian, Southeast Asian, African-American, Afro-
Caribbean or other (each ≤5%). Most patients were
non-smokers. In both groups, most patients were female.
Mean age was numerically higher in the RTX group.
SLE disease characteristics
Disease duration when RTX was initiated was 9.1
±7.1 years, as compared with the significantly shorter
duration for patients treated with conventional IS, 4.1
±6.6 years (table 5).
The major organ manifestations leading to treatment
for both groups were LN, musculoskeletal and haemato-
logical (table 5). Controlling the disease was significantly
higher as the main reason for treatment in the RTX
group, while steroid sparing (and disease control) was
more prevalent in the control group (table 5).
Both SLE Disease Activity Index (SLEDAI) and
SLICC-damage index (DI) were significantly higher at
the start of treatment in the RTX group compared with
conventional IS (table 5). SLEDAI was 12.2±7.1 vs 9.4
±7.0 and SLICC-DI was 1.6±3.4 vs 0.6±1.0. SLEDAI was
significantly higher in LN than in non-LN patients, for
both treatment groups.
Table 2 Patients with SLE on different treatments at
participating sites, sorted by country
Country
Patients
with
SLE
Patients
with
SLE on
RTX (%)
Patients with SLE
on conventional
immunosuppressive
therapy (%)
Belgium* 5000 1 30
Denmark 250 2 50
France* 22 500 1.6† –
Germany 325 4 92
Greece 500 3 –
Hungary 250 1 40
Italy 200–400 3–4 20–62
Spain 5–900 0–11 19–70
Sweden 250–350 4–20 40–65
The
Netherlands
200–275 1–4 20–25
Turkey 600 4 42
UK 450 7 85
*Figures are representative for the whole country.
†Derived from the number of patients (160) in the nationwide
Autoimmunity and Rituximab (AIR) registry, which represents about
50% of patients with SLE on RTX.
RTX, rituximab; SLE, systemic lupus erythematosus.
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Details of treatment in patients with SLE
Among the RTX-treated patients, data on previous treat-
ments were available for 95 patients of whom 82 (86%)
had previously received ISs and 13 had not. The previ-
ous ISs included CYX (46%), mycophenolate mofetil
(40%), azathioprine (35%), methotrexate (12%) and
other ISs (21%, mainly ciclosporin A and intravenous Ig)
(table 6). Most patients (69%) had been treated with
one or two different ISs prior to RTX, and 17% had
been treated with three or more.
Previous treatments for the conventional IS-treated
patients included azathioprine (28%), CYX (26%),
mycophenolate mofetil (17%), methotrexate (10%) and
other ISs (6%). Many patients in this group (49%) had
not been previously treated with any ISs, and among
those who had, the majority had one or two different ISs.
Two different dosing regimens for RTX were used:
375 mg/m2×4 (36%) and 1000 mg×2 (64%).
Concomitant CYX was used in 40% of patients, most
with LN (data not shown). At the time of RTX initiation,
Table 3 Estimates of the overall number of patients with SLE, and patients on RTX, by country
Country Population Patients with SLE *
SLE/
10.000†
Patients with SLE
on RTX‡ Reference§
Belgium 10 839 905 5000 7.0 52 (1.0%) PC
Denmark 5 511 000 1000 2.7 10 (1.0%) CRF35
France 61 538 322 22 500 5.5 360 (1.6%) PC
Germany 82 217 837 5000–30 000 0.9–5.5 150 (0.5%–3.0%) CRF36
Greece 10 760 136 2800–7800 4–11 80–100 (1.0%–3.5%) PC37 38
Hungary 10 045 000 3000–4500 4.5–6.8 15 (0.3%–0.5%) CRF
Italy 58 133 509 5500–30 000 1.4–7.8 70–150 (0.2%–2.7%) CRF, PC
Spain 46 030 109 15 000–40 000 4.9–13.2 150–450 (0.4%–3.0%) CRF39 40
Sweden 9 471 174 3000–4000 4.8–6.4 80–135 (2%–4.5%) CRF41
The Netherlands 16 594 107 3000–4500 2.7–4.1 16–120 (0.4%–4.0%) CRF
Turkey 73 723 000 27 700–34 000 4.6–7.0 40 (0.1%) CRF42
UK 61 113 210 25 000 6.2 150–300 (0.6%–1.2%) CRF27 43 44
Total 118 500–208 300 1173–1882 (0.6%–1.6%)
Remaining EEA countries¶
Austria** 8 400 000 500–3000 0.9–5.5 15 (0.5%–3%)
Bulgaria†† 7 504 868 2200–3400 4.5–6.8 11 (0.3%–0.5%)
Cyprus‡‡ 854 000 225–600 4–11 6–8 (1.0%–3.6%)
Czech Republic†† 10 327 000 3100–4600 4.5–6.8 15 (0.3%–0.5%)
Estonia†† 1 338 000 400–600 4.5–6.8 2 (0.3%–0.5%)
Finland§§ 5 399 090 1700–2300 4.8–6.4 46–77 (2.0%–4.5%)
Iceland§§ 320 000 100–135 4.8–6.4 3–5 (2.2%–3.7%)
Ireland¶¶ 4 459 300 1800 6 11–22 (0.6%–1.2%) 45
Latvia†† 2 263 000 700–1000 4.5–6.8 3 (0.3%–0.4%)
Liechtenstein** 33 717 2–12 0.9–5.5 0
Lithuania†† 3 338 700 1000–1500 4.5–6.8 5 (0.3%–0.5%)
Luxembourg** 465 000 30–150 1–5 1 (0.7%–3.3%)
Malta‡‡ 417 608 110–300 4–11 3–4 (1.0%–3.6%)
Norway§§ 4 920 300 1600–2100 4.8–6.2 42–70 (2.1%–4.5%)
Poland†† 38 038 000 11 300–17 100 4.5–6.8 57 (0.3%–0.5%)
Portugal*** 10 605 870 4100–9200 5.9–13.2 35–104 (0.4%–2.5%)
Romania†† 21 462 186 6400–9600 4.5–6.8 32 (0.3%–0.5%)
Slovakia†† 5 411 000 1600–2400 4.5–6.8 8 (0.3%–0.5%)
Slovenia†† 2 010 347 600–900 4.5–6.8 3 (0.3%–0.5%)
Total for countries under
EMA jurisdiction
573 545 295 155 967–268 997 4.1–7.1 1471–2324
(0.5%–1.5%)
*Data obtained from CRFs or journal references.
†Prevalence of SLE was calculated from the information provided in the CRFs and calculated from the adult population (adults=66% of the
total population)) or journal references.
‡Figures obtained from the CRFs or journal references.
§Source of information is CRF, personal communication (PC) or journal reference.
¶Croatia is not included, as it was not a member of EU or EEA (European Economic Area) when data were collected.
**Assumed similar to Germany.
††Assumed similar to Hungary.
‡‡Assumed similar to Greece.
§§Assumed similar to Sweden.
¶¶Assumed similar to UK.
***Assumed similar to Spain.
CRF, case report forms; EMA, European Medicines Agency; RTX, rituximab; SLE, systemic lupus erythematosus.
4 Rydén-Aulin M, Boumpas D, Bultink I, et al. Lupus Science & Medicine 2016;3:e000163. doi:10.1136/lupus-2016-000163
Lupus Science & Medicine
group.bmj.com on October 19, 2016 - Published by http://lupus.bmj.com/Downloaded from 
concomitant glucocorticoids were used in 68% of the
patients. For patients treated with conventional IS, con-
comitant glucocorticoids were used in 94% of the
patients. The most commonly initiated IS was mycophe-
nolate mofetil (45%), followed by azathioprine (24%),
CYX (8%) and methotrexate (6%).
DISCUSSION
We have performed a large European survey to assess
the off-label use of RTX for the treatment of SLE, specif-
ically investigating the extent to which rheumatologists
use RTX compared with conventional ISs to treat
patients with SLE. We have also looked at the character-
istics of RTX-treated patients compared with patients
treated conventionally.
One should keep in mind that treatment duration for
RTX is poorly defined, because the biological effect may
last from months to years.28 For this survey, we collected
data for RTX treatment during a given time, and may
therefore have missed a small number of patients given
the treatment before that time and still benefiting from
its effects.
Our study indicates that RTX is used off-label in
European countries in 0.5%–1.5% of all patients with
SLE. Because this study was limited to rheumatology spe-
cialty centres, the true usage of RTX may be somewhat
higher but likely to remain in the same single-digit per-
centage range, indicating that the use of RTX is restrict-
ive. Significant heterogeneity in the off-label use of RTX
was also observed. In some countries, off-label use is dis-
couraged through regulatory or reimbursement mechan-
isms rendering use impossible in practical terms. In
other European countries, off-label use can be both per-
mitted and fully reimbursed when motivated by the clin-
ical situation. Such is the case in Sweden, where this
Table 4 Demographics of patients with SLE
RTX N IS N p Value
Gender 91% Female 103 89% Female 72 NS
Age, mean±SD 36.5±12.0 101 33.7±11.6 72 0.124
Smoking status 69% Never
14% Past
17% Current
72 74% Never
12% Past
14% Current
72 NS
NS
NS
Ethnicity 93% Caucasian
5% African-American
1% Southeast Asian
1% Other
103 91% Caucasian
3% Latino/South African
3% Asian/Indian subcontinent
1% Southeast Asian
1% Caribbean/Afro-Caribbean
1% Other
72 NS
IS, immunosuppressive; NS, not significant; RTX, rituximab; SLE, systemic lupus erythematosus.
Table 5 SLE disease characteristics for patients with SLE treated with RTX and conventional IS
RTX N IS N p Value
Disease duration years, mean±SD 9.1±7.1 101 4.1±6.6 72 <0.0001
Organ manifestation (%) 103 (%) 72
Renal (LN) 58 53 NS
Musculoskeletal 11 22 0.038
Haematological 15 11 NS
Skin 6 6 NS
CNS 7 3 NS
Other 3 5 NS
Reason for treatment (%) 103 (%) 72
Controlling disease 77 44 <0.0001
Steroid-sparing 1 14 <0.0001
Both 22 42 0.006
Disease activity
SLEDAI, mean±SD 12.2±7.1 102 9.4±7.0 72 0.010
SLICC-DI, mean±SD 1.6±3.4 96 0.6±1.0 72 0.014
SLEDAI, LN vs
non-LN*
14.6±6.2 vs
9.0±6.9
59
43
12.5±7.6 vs
5.9±4.3
38
34
<0.0001
(within groups treatments)
*SLEDAI between groups, treatments: LN, NS; non-LN p=0.029.
CNS, central nervous system; IS, immunosuppressive; LN, lupus nephritis; NS, not significant; RTX, rituximab; SLE, systemic lupus
erythematosus; SLICC, Systemic Lupus International Collaborating Clinics.
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report originated and where the off-label use of RTX in
SLE was the highest among the countries surveyed
(table 3). However, this may change, in part because
RTX is now recommended in both European League
Against Rheumatism (EULAR) and ACR guidelines for
refractory LN, and in part because less expensive biosi-
milars for RTX may become available.
A comparison between patients treated with RTX and
those treated with conventional ISs was made to analyse
similarities and differences between the two groups.
Patients treated with RTX were on average somewhat
older and had longer disease duration. The character-
istics of patients treated with RTX in this study suggest
a clear focus on patients with high disease activity
(table 5). As measured by the SLEDAI, where 10 or
greater is usually considered ‘severe’ disease, the average
disease activity of the RTX-treated patients was 12.2 com-
pared with 9.4 in the control group. For the RTX group,
the average SLICC-DI was 1.6 compared with 0.6 for the
control group. Longitudinal studies have demonstrated
that even a single point on this damage scale associates
with significantly lower quality of life, higher rates of
flares and end-organ complications, as well as shorter
life expectancy.29–31 Both findings support the hypoth-
esis that RTX is chosen for patients with more severe
lupus.
The organ systems for which RTX and the conven-
tional agents were chosen did not differ as much as
might have been expected. LN was present in about half
the patients in each group (table 5). This is the organ
manifestation by far the most studied and for which the
evidence is most clear that aggressive immunosuppres-
sive or immunomodulatory treatment can be beneficial.
It has been shown for early LN to have a substantial cor-
ticoid sparing effect.32 Musculoskeletal manifestations
were under-represented among patients treated with
RTX compared with those treated with conventional ISs.
This may be explained by the fact that one of the ISs
used, methotrexate, is by far the most widely used anti-
rheumatic agent for patients with inflammatory
arthritides. Therefore, rheumatologists may be more
inclined to use this drug for patients with musculoskel-
etal lupus. Also, the use of RTX for musculoskeletal SLE
was strongly discouraged by the negative results of the
EXPLORER trial.33 In contrast to musculoskeletal lupus,
there was a small numerical over-representation of
haematological manifestations (thrombocytopenia and/
or haemolytic anaemia) in patients treated with RTX,
which may be explained by the strong link between
haematological lupus and autoantibodies and the
impression that autoantibody-mediated lupus manifesta-
tions may be particularly susceptible for RTX treatment.
The proportion of patients with predominant mucocu-
taneous lupus was strikingly lower than that would be
expected based on the prevalence of such manifesta-
tions in the overall SLE population, suggesting that
neither immunosuppressive is perceived as effective for
mucocutaneous lupus. Indeed, there is only limited evi-
dence for their efficacy.
While RTX was typically identified by the clinician as a
treatment to control disease activity, conventional ISs
were used primarily for corticosteroid-sparing purposes,
consistent with recent emphasis in lupus therapeutics on
minimising corticosteroid exposure34 (table 5). In this
group, the start of conventional IS treatment was often
accompanied by high glucocorticoid dosages. Although
not specifically queried, we believe this reflects the clini-
cian’s concern that conventional ISs are slow-acting
agents, requiring several months or more to achieve
disease control. Highly active SLE must therefore ini-
tially be controlled through the addition of moderate–
high glucocorticoid dosages (‘bridging therapy’).
Patients treated with RTX had a history of more use of
conventional ISs than the control group. This supports
the view that RTX is used after conventional therapeutic
options have been exhausted (table 6).
This study was based on various sources of informa-
tion, and the hierarchy of evidence was assigned in the
following order: registry-based datasets, CRFs submitted
by the participating investigators, published data from
the literature and responses to specific queries. Each of
these sources carries some limitations. Common to all is
that data were collected, collated and analysed
retrospectively.
The overall methodology is, in large part, ‘sensible
extrapolation’. Thus, most of the primary data reflect
the situation in individual centres, regions, or, in some
instances, countries. From these data, countrywide esti-
mates of RTX use for SLE were derived, which—except
for the few countries that provided countrywide data—
entailed extrapolation. In order to make this as reliable
as possible, additional support was taken from the litera-
ture and from direct contact with investigators. Estimates
obtained for some of the EU countries were extrapo-
lated to countries that were not represented in the data-
sets for this study. Countries used for this extrapolation
were chosen based on cultural and geographical similar-
ities. Finally, the results obtained may not be applicable
Table 6 Previous conventional immunosuppressives
Previous ISs
RTX
(%) N=95
IS
(%) N=72 p Value
Cyclophosphamide 46 26 0.009
Mycophenolate mofetil 40 17 0.001
Azathioprine 35 28 NS
Methotrexate 12 10 NS
Other 21 6 0.005
No ISs 14 49 <0.0001
Number of previous
ISs % N=95 % N=72
0 14 49 <0.0001
1–2 69 41 <0.0001
3–5 17 10 NS
IS, immunosuppressive; NS, not significant; RTX, rituximab.
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to all countries, as most patients in the study are
Caucasian.
Another significant limitation was the focus on the
rheumatology specialty. Because patients with more
severe SLE are usually treated by rheumatology specialists,
our initial approach seemed reasonable. Since RTX has
been proposed in the literature as a potential alternative
in the treatment of LN, and since LN can exist almost
completely in isolation in the individual patient (ie,
without other significant lupus manifestations), it is con-
ceivable that some patients with LN are treated with RTX
solely by nephrologists. Therefore, it may be more accur-
ate to say that this study estimates the use of RTX for SLE
within the rheumatology specialty. The possibility that
other specialists (eg, dermatologists, neurologists, haema-
tologists) would treat patients with SLE with RTX without
the involvement of a rheumatologist is more remote.
In summary, this study on the off-label use of RTX in
SLE has provided a number of insights into hitherto
underexplored lupus therapeutics. The pattern of RTX
use suggests that it is limited to specialised, tertiary care
centres. The fact that currently only a relatively small
proportion of patients are treated with RTX, and that
these patients in general have been treated with multiple
immunosuppressives previously, suggests that RTX is
chosen only for patients for whom all reasonable con-
ventional options have been exhausted. Moreover, RTX
is used in patients with high disease activity and a signifi-
cant burden of SLE-related damage. As such, the
current usage of RTX in SLE may be considered conser-
vative, representing an appropriately used medication of
last resort for those with the highest medical need
within the larger patient population with SLE.
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